A little-known immune protein in the brain may hold clues to stopping Parkinson’s in its tracks—but the media hype is already racing ahead of the science.
Story Snapshot
- Scientists have tied a brain immune protein, GPNMB, to how Parkinson’s damage spreads between cells.
- New lab work shows antibodies blocking GPNMB can stop toxic proteins from spreading in cultured neurons.
- Human genetics and blood tests link higher GPNMB to greater Parkinson’s risk and more severe disease.
- Despite breathless headlines, all evidence so far is preclinical—no proof yet that blocking GPNMB helps real patients.
What Scientists Just Found About Parkinson’s “Spread Protein”
Researchers at the University of Pennsylvania report that a protein called glycoprotein nonmetastatic melanoma B, or GPNMB, appears to help toxic Parkinson’s proteins move from one brain cell to another, potentially driving the disease’s relentless march through the nervous system.[4] Earlier work from the same group, published in the journal Science in 2022, linked a known Parkinson’s risk spot on chromosome 7 directly to GPNMB and showed that this protein physically interacts with alpha-synuclein, the central protein in Parkinson’s pathology.[2]
The 2022 Science study used human genetic data, brain tissue, and cell models and concluded that GPNMB was both “necessary and sufficient” for brain cells to take up fibrillar, or clumped, alpha-synuclein and develop the abnormal protein deposits that mark Parkinson’s disease.[2] In those cell experiments, when scientists removed or reduced GPNMB, cells struggled to pull in the toxic alpha-synuclein clumps, and the resulting protein pathology dropped sharply.[1] When they restored or increased GPNMB, uptake and pathology returned, underscoring how central this protein appears in that system.[1]
How Blocking GPNMB Worked in Lab Models
In the newest study, summarized by Penn Medicine, scientists tracked where GPNMB is made in the brain and how it behaves once neurons are injured.[4] They report that microglia—the brain’s resident immune cells—ramp up production of GPNMB when they are near damaged or dying neurons.[4] Enzymes then clip GPNMB off the cell surface, releasing part of the molecule so it can move freely between cells, fitting a pattern where it could help spread alpha-synuclein pathology from one area of the brain to another.[4]
Crucially, Penn’s team says that monoclonal antibodies engineered to block GPNMB were able to stop alpha-synuclein pathology from spreading between cultured neurons in preclinical experiments.[4][6] According to the press release, when GPNMB was blocked, the toxic alpha-synuclein did not move as efficiently from injured cells to nearby healthy ones, interrupting what the authors describe as a “self reinforcing cycle” of injury, GPNMB release, and further spread.[4] People with genetic variants that drive higher GPNMB levels also showed more extensive alpha-synuclein buildup in human data, reinforcing the idea that this protein is not just a bystander.[4]
Human Clues: Risk Gene and Blood Marker, Not Yet a Cure
The earlier Science paper adds two key human pieces to the puzzle: genetics and blood measurements.[2] Using large genetic studies, the researchers found that a Parkinson’s risk signal called rs199347 overlaps with a region that controls GPNMB expression in the human brain, with a reported 94 percent probability that the same underlying change drives both the disease risk and higher GPNMB levels in the caudate region.[2] That kind of “colocalization” analysis is one of the strongest tools scientists use to argue that a gene is causally tied to a risk signal.[2]
On the biomarker front, the same Science study measured GPNMB in blood plasma from 731 people with Parkinson’s and 59 healthy controls.[2] They found that GPNMB levels were elevated in patients, and that higher levels tracked with more severe disease, suggesting the protein may reflect how advanced the illness is.[2] Later work looking at cerebrospinal fluid GPNMB also reported links with disease severity and age at onset, but still used careful language like “possible relationship,” underscoring that these are associations, not definitive proof that GPNMB drives progression.[6]
Why This Is Promising—but Still Preliminary
Supporters of the GPNMB story argue that it checks several important boxes for a drug target: human genetic linkage to risk, a plausible biological mechanism, cell-based proof that GPNMB is necessary and sufficient for alpha-synuclein uptake, and biomarker evidence tying higher levels to worse disease.[1][2][4] The Penn group and related coverage suggest that targeting GPNMB to block the spread of disease-associated alpha-synuclein could be a useful treatment strategy, especially early in the disease before damage becomes widespread.[4]
However, every strong claim so far comes from cell systems, cultured neurons, and early biomarker work, not from real-world patient trials.[2][3][4][6] The antibody experiments blocking GPNMB spread are described only in university press material, not yet in the full Neuron paper with detailed methods, doses, and replication data.[3][4] No available source shows that blocking GPNMB slows Parkinson’s progression, preserves movement, or improves quality of life in people.[2][3][6] Media headlines about “stopping Parkinson’s in its tracks” risk collapsing correlation into causation long before that higher bar is met.[3]
Sources:
[1] Web – Researchers block key protein that helps Parkinson’s spread through …
[2] Web – GPNMB confers risk for Parkinson’s disease through interaction with …
[3] Web – GPNMB confers risk for Parkinson’s disease through … – Science
[4] Web – Immune protein a possible target to slow Parkinson’s disease
[6] Web – Immune protein a possible target to slow Parkinson’s disease
